In December 2019, coronavirus disease 2019 (COVID-19), a new de novo infectious disease, was first identified in Wuhan, China and quickly spread across China and around the world. The etiology was a novel betacoronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Lu et al., [@B6]). On Mar. 11, 2020, World Health Organization (WHO) characterized COVID-19 as a global pandemic. As of Mar. 22, 2020, over 292 000 confirmed COVID-19 cases have been reported globally. To date, COVID-19, with its high infectivity, has killed more people than severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) combined (Wu and McGoogan, [@B14]).

Researchers are continuing to rigorously document and analyze clinical and radiological findings from laboratory-confirmed COVID-19 patients so that the clinical, laboratorial, and radiological changes in these patients can be better understood (Chen et al., [@B2]; Chung et al., [@B3]; Guan et al., [@B4]; Huang et al., [@B5]; Pan YY et al., [@B9]; Shi et al., [@B10]; Song et al., [@B11]; Wang et al., [@B12]). Records showed that common symptoms include fever and respiratory symptoms including dry cough and sore throat. Laboratory test results showed that lymphopenia is present in most cases and that lung abnormalities usually present as viral pneumonia, similar to other kinds of viral pneumonia (Yin and Wunderink, [@B16]).

Computed tomography (CT) scans, as a sensitive modality that detects changes in the lungs, are playing an important role in the evaluation and management of COVID-19 patients. Progressive airspace opacities and multifocal patchy subpleural ground-glass opacifications (GGOs) have been recorded as among the most common initial CT appearances of COVID-19 (Bernheim et al., [@B1]; Shi et al., [@B10]; Zu et al., [@B17]). However, the relationship between CT imaging features and clinical features remains unclear. In this study, we analyze initial chest CT images of patients with COVID-19 to determine the natural history of lung abnormalities and the relation of these characteristics with clinical features. These findings may help researchers and practitioners to more fully understand the clinical course and lung changes prompted by COVID-19 infection and possibly lead to improved methods in public health surveillance and evaluation.

Data for this study were taken from records of 36 patients with confirmed COVID-19 who were admitted to hospital from Jan. 16 to Feb. 6, 2020. Demographic and clinical data were obtained from all patients, including severity and time course of symptoms, laboratory results, and patient histories, including exposure. Data for this analysis for each patient included the duration from the onset of symptoms to the initial CT scan, fever measurements (including highest temperature and the duration from fever onset to CT scan), and white blood cell counts. Other blood parameters were not included due to limited data availability.

All CT images were reviewed by two experienced radiologists who used scoring method described by Chung et al. ([@B3]) to evaluate the extent of involvement for each of the five lung lobes. Score 0, signified normality; Score 1, 1%--25% of the total lobe area; Score 2, 26%--50% of the total lobe area; Score 3, 51%--75% of the total lobe area; Score 4, 76%--100% of the total lobe area. The overall lung "CT score" was obtained by summing the five lung lobe scores (range, 0--20).

As indicated in Table [1](#T1){ref-type="table"}, patients in this study had a median age of 46 years (interquartile range (IQR), 34--55 years). The median interval between onset and initial CT scanning was 4 d with IQR of 2--7 d. Among them, 33 (91.7%) patients presented with fever, and 30 of them (83.3%) experienced fever as the initial symptom. Thirty-one (86.1%) patients had low or middle fever (lower than 39 °C). As three patients did not have fever, the median interval between fever onset and CT scanning was 3 d with IQR of 1--7 d. On admission, 10 patients (27.8%) had leucopenia (white blood cell count \<4×10^9^ L^−1^), 20 (55.6%) had lymphopenia (lymphocyte percentage \<20%), and 24 (66.7%) had neutrophilia (neutrophil percentage \>70%).

###### 

Clinical features of 36 patients with COVID-19 on admission

  Clinical feature                               Value[\*](#T1FN1){ref-type="fn"}
  ---------------------------------------------- ----------------------------------
  Sex                                            
   Men                                           14 (38.9)
   Women                                         22 (61.1)
  Age (year)                                     46 (34--55)
  Exposure history                               
   Recent travel to Wuhan                        24 (66.7)
   Exposure to infected patient                  7 (19.4)
   Unknown exposure                              5 (13.9)
  Fever                                          33 (91.7)
   Highest temperature (°C)                      38.3 (37.7--38.9)
   \<37.3                                        3 (8.3)
   37.3--38.0                                    14 (38.9)
   38.1--39.0                                    17 (47.2)
   \>39.0                                        2 (5.6)
  Other symptoms                                 
   Cough                                         24 (66.7)
   Sputum production                             8 (22.2)
   Sore throat                                   11 (30.6)
   Chills/rigor                                  9 (25.0)
   Rhinorrhoea                                   4 (11.1)
   Shortness of breath                           6 (16.7)
   Headache/dizziness                            6 (16.7)
   Muscle pain/fatigue                           15 (41.7)
   Diarrhea                                      1 (2.8)
  Duration from onset to CT scanning (d)         4 (2--7)
  Duration from fever onset to CT scanning (d)   3 (1--7)
  WBC count (×10^9^ L^−1^)                       5.3 (3.7--7.0)
   \<4                                           10 (27.8)
   4--10                                         25 (69.4)
   \>10                                          1 (2.8)
  Neutrophil count (×10^9^ L^−1^)                3.7 (2.7--5.4)
   \<50%                                         3 (8.3)
   50%--70%                                      9 (25.0)
   \>70%                                         24 (66.7)
  Lymphocyte count (×10^9^ L^−1^)                1.0 (0.6--1.2)
   \<20%                                         20 (55.6)
   20%--40%                                      11 (30.6)
   \>40%                                         5 (13.9)

Values are expressed as number (percentage) or median (interquartile range, IQR). CT, computed tomography; WBC, white blood cell

Fig. [1](#F1){ref-type="fig"} presents the results of correlations between CT score and clinical data. CT scores were positively correlated with age (*r*=0.333, *P*=0.048) and with the duration from onset to CT scanning (*r*=0.666, *P*\<0.001). CT scores correlated well with the duration from fever onset to CT scanning (*r*=0.698, *P*\<0.001), and a marginally significant correlation was observed between CT scores and the highest temperature (*r*=0.290, *P*=0.086). Additionally, CT scores were negatively correlated with the lymphocyte count (*r*=−0.495, *P*=0.002), but positively correlated with the neutrophil count (*r*=0.385, *P*=0.021). The imaging features of lung lesions from early to late stage are showed in the supplementary materials (Document [S1](#DS1){ref-type="supplementary-material"}).
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In this study, we investigated the initial CT features in COVID-19 patients and correlated results with their clinical features. Viral pneumonia developed in 94.4% of infected patients, presenting with GGO or/and consolidation with a focal or diffuse distribution, findings similar to those previously described (Chung et al., [@B3]; Pan YY et al., [@B9]; Shi et al., [@B10]; Song et al., [@B11]). In addition, the lung involvement was positively correlated with the duration of symptoms in all patients. These lung abnormalities were observed in the initial patient CT images and none necessitated any interventions. Our findings indicate that in the natural progress of SARS-CoV-2 infection, lung lesions become more sever with longer duration of symptoms, results consistent to those of infections just as SARS (Ooi et al., [@B7]). Recent studies have also shown that lung involvement increases rapidly after the onset of symptoms (Bernheim et al., [@B1]; Pan F et al., [@B8]).

More than 90% patients with COVID-19 developed fever during the disease course, with 90.9% of these patients exhibiting fever as their first symptom. Similar results were reported in recent studies (Huang et al., [@B5]; Wang et al., [@B12]), as well as in other viral pneumonia caused by coronavirus, such as SARS and MERS (Yin and Wunderink, [@B16]). Wu et al. ([@B13]) have also documented that the extent of lung lesions has been positively correlated with the duration and degree of fever.

To date, there is limited evidence about the pathophysiology about the COVID-19. It was reported that SARS-CoV-2 infection induced increased concentrations of proinflammatory cytokines (interleukin-1β (IL-1β), IL-4, IL-10, interferon-γ (IFN-γ), IFN-γ-inducible protein-10 (IP10), and monocyte chemoattractant protein-1 (MCP1)) (Huang et al., [@B5]) and decreased lymphocytes in patients with COVID-19 (Chen et al., [@B2]; Wang et al., [@B12]). Overactivation of T cells observed in at least one pathological study (Xu et al., [@B15]) suggests that virus particles spread through the respiratory mucosa and infected other cells induced a cytokine storm in the body. This response is thought to have generated a follow on series of immune responses (mainly cellular immune) and caused changes in peripheral white blood cells and immune cells (especially T lymphocytes), in turn resulting in diﬀuse alveolar damage. Data from both this and one previous study (Wu et al., [@B13]) indicate that there are correlations between degree of lung lesions and observed white blood cell count. The negative correlation between lung involvement and lymphocyte count in peripheral blood (*r*=−0.260, *P*\<0.05) (Wu et al., [@B13]) provided more information that lymphopenia might be the hallmark of the exacerbations of COVID-19. Further studies are necessary to characterize the pathology and pathogenesis in COVID-19, which will help to improve our understanding of the disease.

Notably, there were some outlier results in this study in two teenager patients. Both patients did have fever, went to hospital on the first day and third day of onset symptom, respectively, but were admitted with normal CT. Three other patients were admitted with mild lung abnormalities, mild symptoms, and no fever. These suggested that early presentation to the healthcare center for testing helped to diagnose the disease in mild stage and allowed for better prognosis.

This study has several limitations. First, the sample size of our study was small, and most patients presented with mild illness. Therefore, the findings may not be extended in patients with a severe disease. Second, CT images of one patient were acquired with 5-mm slice thickness, which might influence the precision of lesion evaluation. Third, due to limited data availability, it is impossible to assess the relationship between CT features and other clinical data, and continued observations of the disease course are needed.

Our results of lung abnormalities in the natural history of 36 COVID-19 patients with mild symptoms showed that there was a correlation of disease severity in chest CT findings with the duration of symptoms, especially fever, and that lymphopenia might be a marker of exacerbations of COVID-19.
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